ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
Crunch time approaches for UroGen.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
Minghui’s MHB088C will soon start phase 3 in China.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.